<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02604992</url>
  </required_header>
  <id_info>
    <org_study_id>INS004-15-059</org_study_id>
    <nct_id>NCT02604992</nct_id>
  </id_info>
  <brief_title>Comparative Bioavailability of Dronabinol Oral Solution in Healthy Volunteers</brief_title>
  <official_title>An Open-Label, Randomized, Single-Dose, Two-Period, Two-Way Crossover Comparative Bioavailability Study of Dronabinol Oral Solution, 4.25 mg to Marinol Capsule, 5 mg in Healthy Volunteers Under Fed Conditions</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>INSYS Therapeutics Inc</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>INSYS Therapeutics Inc</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The primary objective of this study is to evaluate the comparative bioavailability of a test
      product of dronabinol oral solution administered under fed conditions to the reference listed
      drug (RLD) administered to participants under fed and fasted conditions.

      The secondary objective is to compare the onset of detectable dronabinol concentrations
      between dronabinol oral solution and the RLD.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>November 2015</start_date>
  <completion_date type="Actual">December 2015</completion_date>
  <primary_completion_date type="Actual">December 2015</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Area under the curve from time 0 to the last measured concentration</measure>
    <time_frame>0 hour (predose), 0.08 (5 min), 0.17 (I0 min), 0.25 (15 min), 0.5 (30 min), 0.75 (45 min), 1.0, 1.5, 2.0, 2.5, 3.0, 3.5, 4.0, 6.0, 8.0, 12, and 16 hours postdose.</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Area under the curve extrapolated to infinity</measure>
    <time_frame>0 hour (predose), 0.08 (5 min), 0.17 (I0 min), 0.25 (15 min), 0.5 (30 min), 0.75 (45 min), 1.0, 1.5, 2.0, 2.5, 3.0, 3.5, 4.0, 6.0, 8.0, 12, and 16 hours postdose.</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Maximum plasma concentration</measure>
    <time_frame>0 hour (predose), 0.08 (5 min), 0.17 (I0 min), 0.25 (15 min), 0.5 (30 min), 0.75 (45 min), 1.0, 1.5, 2.0, 2.5, 3.0, 3.5, 4.0, 6.0, 8.0, 12, and 16 hours postdose.</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Time to reach maximum plasma concentration</measure>
    <time_frame>0 hour (predose), 0.08 (5 min), 0.17 (I0 min), 0.25 (15 min), 0.5 (30 min), 0.75 (45 min), 1.0, 1.5, 2.0, 2.5, 3.0, 3.5, 4.0, 6.0, 8.0, 12, and 16 hours postdose.</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Elimination rate constant</measure>
    <time_frame>0 hour (predose), 0.08 (5 min), 0.17 (I0 min), 0.25 (15 min), 0.5 (30 min), 0.75 (45 min), 1.0, 1.5, 2.0, 2.5, 3.0, 3.5, 4.0, 6.0, 8.0, 12, and 16 hours postdose.</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>The time prior to the first measurable (non-zero) concentration</measure>
    <time_frame>0 hour (predose), 0.08 (5 min), 0.17 (I0 min), 0.25 (15 min), 0.5 (30 min), 0.75 (45 min), 1.0, 1.5, 2.0, 2.5, 3.0, 3.5, 4.0, 6.0, 8.0, 12, and 16 hours postdose.</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Elimination half-life</measure>
    <time_frame>0 hour (predose), 0.08 (5 min), 0.17 (I0 min), 0.25 (15 min), 0.5 (30 min), 0.75 (45 min), 1.0, 1.5, 2.0, 2.5, 3.0, 3.5, 4.0, 6.0, 8.0, 12, and 16 hours postdose.</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Apparent oral clearance</measure>
    <time_frame>0 hour (predose), 0.08 (5 min), 0.17 (I0 min), 0.25 (15 min), 0.5 (30 min), 0.75 (45 min), 1.0, 1.5, 2.0, 2.5, 3.0, 3.5, 4.0, 6.0, 8.0, 12, and 16 hours postdose.</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Volume of distribution</measure>
    <time_frame>0 hour (predose), 0.08 (5 min), 0.17 (I0 min), 0.25 (15 min), 0.5 (30 min), 0.75 (45 min), 1.0, 1.5, 2.0, 2.5, 3.0, 3.5, 4.0, 6.0, 8.0, 12, and 16 hours postdose.</time_frame>
  </primary_outcome>
  <number_of_arms>6</number_of_arms>
  <enrollment type="Actual">54</enrollment>
  <condition>Healthy</condition>
  <arm_group>
    <arm_group_label>Group 1 (A,B,C)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>With a 7-day washout between periods, participants are randomized to receive Treatment A, Treatment B, and then Treatment C.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group 2 (B,C,A)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>With a 7-day washout between periods, participants are randomized to receive Treatment B, Treatment C, and then Treatment A.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group 3 (C,A,B)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>With a 7-day washout between periods, participants are randomized to receive Treatment C, Treatment A, and then Treatment B.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group 4 (C,B,A)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>With a 7-day washout between periods, participants are randomized to receive Treatment C, Treatment B, and then Treatment A.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group 5 (A,C,B)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>With a 7-day washout between periods, participants are randomized to receive Treatment A, Treatment C, and then Treatment B.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group 6 (B,A,C)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>With a 7-day washout between periods, participants are randomized to receive Treatment B, Treatment A, and then Treatment C.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Treatment A</intervention_name>
    <description>Dronabinol oral solution, under fed conditions</description>
    <arm_group_label>Group 1 (A,B,C)</arm_group_label>
    <arm_group_label>Group 2 (B,C,A)</arm_group_label>
    <arm_group_label>Group 3 (C,A,B)</arm_group_label>
    <arm_group_label>Group 4 (C,B,A)</arm_group_label>
    <arm_group_label>Group 5 (A,C,B)</arm_group_label>
    <arm_group_label>Group 6 (B,A,C)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Treatment B</intervention_name>
    <description>Dronabinol oral capsule, under fed conditions</description>
    <arm_group_label>Group 1 (A,B,C)</arm_group_label>
    <arm_group_label>Group 2 (B,C,A)</arm_group_label>
    <arm_group_label>Group 3 (C,A,B)</arm_group_label>
    <arm_group_label>Group 4 (C,B,A)</arm_group_label>
    <arm_group_label>Group 5 (A,C,B)</arm_group_label>
    <arm_group_label>Group 6 (B,A,C)</arm_group_label>
    <other_name>Marinol</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Treatment C</intervention_name>
    <description>Dronabinol oral capsule, under fasted conditions</description>
    <arm_group_label>Group 1 (A,B,C)</arm_group_label>
    <arm_group_label>Group 2 (B,C,A)</arm_group_label>
    <arm_group_label>Group 3 (C,A,B)</arm_group_label>
    <arm_group_label>Group 4 (C,B,A)</arm_group_label>
    <arm_group_label>Group 5 (A,C,B)</arm_group_label>
    <arm_group_label>Group 6 (B,A,C)</arm_group_label>
    <other_name>Marinol</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Meets protocol-specified criteria for qualification

          -  Fully comprehends and signs the informed consent form, understands all study
             procedures, and can communicate satisfactorily with the Investigator and study
             coordinator

        Exclusion Criteria:

          -  History or current use of over-the-counter medications, dietary supplements, or drugs
             outside protocol-specified parameters

          -  Signs, symptoms or history of any condition that, per protocol or in the opinion of
             the investigator, might compromise:

               1. the safety or well-being of the participant or study staff

               2. the safety or well-being of the participant's offspring (such as through
                  pregnancy or breast-feeding)

               3. the analysis of results
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>50 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Neha Parikh</last_name>
    <role>Study Director</role>
    <affiliation>INSYS Therapeutics Inc</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Worldwide Clinical Trials Early Phase Services, LLC</name>
      <address>
        <city>San Antonio</city>
        <state>Texas</state>
        <zip>78217</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>January 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>November 12, 2015</study_first_submitted>
  <study_first_submitted_qc>November 13, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 16, 2015</study_first_posted>
  <last_update_submitted>January 18, 2016</last_update_submitted>
  <last_update_submitted_qc>January 18, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">January 20, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Comparative Bioavailability</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Dronabinol</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

